Bailard’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $15.5M | Sell |
78,509
-998
| -1% | -$192K | 0.36% | 63 |
|
|
2025
Q4 | $14.6M | Buy |
79,507
+4,801
| +6% | +$842K | 0.32% | 67 |
|
|
2025
Q3 | $11.5M | Buy |
74,706
+3,019
| +4% | +$457K | 0.25% | 85 |
|
|
2025
Q2 | $10M | Sell |
71,687
-3,193
| -4% | -$447K | 0.23% | 96 |
|
|
2025
Q1 | $11M | Buy |
74,880
+356
| +0.5% | +$51.5K | 0.28% | 80 |
|
|
2024
Q4 | $9.77M | Buy |
74,524
+380
| +0.5% | +$53.2K | 0.25% | 92 |
|
|
2024
Q3 | $11.6M | Buy |
74,144
+10,594
| +17% | +$1.71M | 0.3% | 81 |
|
|
2024
Q2 | $9.91M | Buy |
63,550
+643
| +1% | +$96.8K | 0.27% | 86 |
|
|
2024
Q1 | $8.52M | Sell |
62,907
-629
| -1% | -$83.3K | 0.24% | 95 |
|
|
2023
Q4 | $8.56M | Sell |
63,536
-957
| -1% | -$124K | 0.25% | 87 |
|
|
2023
Q3 | $8.73M | Buy |
64,493
+1,777
| +3% | +$243K | 0.29% | 78 |
|
|
2023
Q2 | $8.98M | Sell |
62,716
-7,119
| -10% | -$1.05M | 0.31% | 74 |
|
|
2023
Q1 | $9.69M | Buy |
69,835
+51
| +0.1% | +$6.86K | 0.35% | 68 |
|
|
2022
Q4 | $9.46M | Buy |
69,784
+3,878
| +6% | +$486K | 0.36% | 67 |
|
|
2022
Q3 | $7.23M | Buy |
65,906
+4,561
| +7% | +$579K | 0.3% | 79 |
|
|
2022
Q2 | $8.11M | Sell |
61,345
-3,205
| -5% | -$421K | 0.32% | 70 |
|
|
2022
Q1 | $8.56M | Sell |
64,550
-411
| -0.6% | -$49.3K | 0.29% | 81 |
|
|
2021
Q4 | $7.57M | Sell |
64,961
-4,018
| -6% | -$473K | 0.24% | 94 |
|
|
2021
Q3 | $8.29M | Buy |
68,979
+712
| +1% | +$82.9K | 0.28% | 84 |
|
|
2021
Q2 | $8.18M | Sell |
68,267
-4,399
| -6% | -$483K | 0.28% | 86 |
|
|
2021
Q1 | $7.22M | Buy |
72,666
+55,606
| +326% | +$5.59M | 0.27% | 84 |
|
|
2020
Q4 | $1.71M | Sell |
17,060
-4,185
| -20% | -$443K | 0.08% | 168 |
|
|
2020
Q3 | $2.33M | Buy |
21,245
+533
| +3% | +$59.3K | 0.12% | 140 |
|
|
2020
Q2 | $2.19M | Sell |
20,712
-6,787
| -25% | -$701K | 0.12% | 136 |
|
|
2020
Q1 | $2.46M | Buy |
27,499
+1,919
| +8% | +$181K | 0.17% | 109 |
|
|
2019
Q4 | $2.55M | Sell |
25,580
-2,550
| -9% | -$240K | 0.14% | 129 |
|
|
2019
Q3 | $2.51M | Buy |
28,130
+7,500
| +36% | +$650K | 0.15% | 135 |
|
|
2019
Q2 | $1.7M | Buy |
20,630
+2,000
| +11% | +$157K | 0.1% | 172 |
|
|
2019
Q1 | $1.51M | Buy |
+18,630
| New | +$1.47M | 0.09% | 188 |
|
|
2013
Q4 | – | Sell |
-4,301
| Closed | -$223K | – | 226 |
|
|
2013
Q3 | $223K | Sell |
4,301
-31,701
| -88% | -$1.59M | 0.04% | 193 |
|
|
2013
Q2 | $1.7M | Buy |
+36,002
| New | +$1.83M | 0.31% | 69 |
|
Other funds holding AZN
IA
VCM
VAM
Bailard's AZN Position: Q1 2026 in Review
Bailard reduced its AstraZeneca (AZN) stake by 1.3% in Q1 2026, selling an estimated $192K and leaving 78,509 shares worth $15.5M. The position accounts for 0.36% of the portfolio, ranked #63.
Bailard first reported a position in AZN in Q2 2013 and has held it in 31 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Bailard held 78,509 shares of AstraZeneca worth $15.5M as of Q1 2026.
- Bailard sold 998 AstraZeneca shares in Q1 2026, an estimated $192K.
- AstraZeneca made up 0.36% of Bailard's portfolio in Q1 2026, its #63 holding.
- Bailard first reported a position in AstraZeneca in Q2 2013 and has held it in 31 quarters since.
- 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Bailard's 13F filing for Q1 2026, filed 11 May 2026.